The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to ...

Treatment MarketThe global urinary tract infection (UTI) treatment market is poised for consistent growth, with an estimated ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...

Game-changer' drug Hiprex is set to be approved for NHS use - but there is still no official guidance for treating chronic ...

Ciprofloxacin resistance in E. coli UTI is increasing. The use of this antimicrobial agent as empirical therapy for UTI should be reconsidered and efforts should be made to limit its use to ...

A mild UTI may last days or under a week. These are sometimes called uncomplicated UTIs. Learn how long a complicated UTI ...

Urologists share the most effective ways to soothe pain and discomfort with UTI home remedies.

The treatment has been shown to be active against third generation cephalosporin-resistant Enterobacterales species. Orlynvah combines sulopenem etzadroxil, a penem antibacterial drug, and ...

In uncomplicated cases, urinary tract infections are easily treated with a short course of antibiotics, although resistance to many of the antibiotics used to treat this condition is increasing.

Most urinary tract infections (UTIs) are caused by the E. coli bacteria, which are treated with antibiotics. But some strains may be resistant to common antibiotic types. For the most part, E.

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

“Across Australia, no matter which health profession you’re in, we need to be vigilant with our use of antibiotics, and this protocol ensures that we’re only using it where appropriate.” The change ...